Abstract
The echinocandins—caspofungin, anidulafungin and micafungin—are semi-synthetic cyclic hexapeptide antimicrobial agents with modified N-linked acyl lipid side chains which anchor the compounds to the phospholipid bilayer of the fungal cell membrane, thereby inhibiting synthesis of fungal cell wall glucan. Over the last 10 years, echinocandins have become the first-line antifungal treatment of candidaemia and other forms of invasive candidiasis (IC). Echinocandins are generally well tolerated, but their use is limited by their requirement for daily intravenous dosing, lack of oral formulation and limited spectrum. In critically ill patients, it is also recognised that achievement of their pharmacokinetic/pharmacodynamic targets shows large inter-individual variability. As a drug class, they are safe to use and are associated with few adverse reactions and few drug–drug interactions of significance. Recent discovery of their ability to prevent and treat Candida biofilm formation particularly in the presence of invasive medical devices and also their ability to penetrate into mucosal surfaces such as vulvovaginal candidiasis has opened up new opportunities for research into their drug delivery. New dosing intervals are being explored to allow less frequent intravenous dosing in the ambulatory setting, and a new long-acting echinocandin, CD101, is being developed for weekly and topical administration.
Similar content being viewed by others
References
Aguilar-Zapata D, Petraitiene R, Petraitis V (2015) Echinocandins: the expanding antifungal armamentarium. Clin Infect Dis 61(Suppl 6):S604–S611
Alothman AF, Al-Musawi T, Al-Abdely HM, Salman JA, Almaslamani M, Yared N et al (2014) Clinical practice guidelines for the management of invasive Candida infections in adults in the Middle East region: expert panel recommendations. J Infect Public Health 7(1):6–19
Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A (2010) In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother 54(6):2497–2506
Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, Graybill JR et al (2002) In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother 46(11):3591–3596
Bohn JB (1995) JN. (1-3)-b-D-Glucans as biological response modifiers: a review of structure-functional activity relationships. Carbohydr Polym 28:3–14
Brown GD, Gordon S (2003) Fungal beta-glucans and mammalian immunity. Immunity 19(3):311–315
Castanheira M, Messer SA, Rhomberg PR, Pfaller MA (2016) Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013). Diagn Microbiol Infect Dis 85(2):200–204
Chen SC, Slavin MA, Sorrell TC (2011) Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 71(1):11–41
Chen SC, Sorrell TC, Chang CC, Paige EK, Bryant PA, Slavin MA (2014) Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. Intern Med J 44(12b):1315–1332
Cleary JD, Stover KR (2015) Antifungal-associated drug-induced cardiac disease. Clin Infect Dis 61(Suppl 6):S662–S668
Coad B, Lamont-Friedrich SJ, Gwynne L, Jasieniak M, Griesser SS, Traven A, Peleg AY, Griessera HJ (2015) Surface coatings with covalently attached caspofungin are effective in eliminating fungal pathogens. J Mater Chem B 3:8
Coad BR, Griesser HJ, Peleg AY, Traven A (2016) Anti-infective surface coatings: design and therapeutic promise against device-associated infections. PLoS Pathog 12(6):e1005598
Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ et al (2007) Posaconazole versus fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356(4):348–359
Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):19–37
Cushion MAA, Lynch K, Linke MJ (2016) Prevention of pneumocystis pneumonia (PCP) by the novel echinocandin, CD101. ASM Microbes 2016; June 16–20, Boston, MA2016
Denning DW (2003) Echinocandin antifungal drugs. Lancet 362(9390):1142–1151
Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C et al (2006) Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 53(5):337–349
Fink M, Zerlauth U, Kaulfersch C, Rab A, Alberer D, Preiss P et al (2013) A severe case of haemodynamic instability during anidulafungin administration. J Clin Pharm Ther 38(3):241–242
Fuchs BB, Li Y, Li D, Johnston T, Hendricks G, Li G et al (2016) Micafungin elicits an immunomodulatory effect in galleria mellonella and mice. Mycopathologia 181(1–2):17–25
Garcia R, Botet J, Rodriguez-Pena JM, Bermejo C, Ribas JC, Revuelta JL et al (2015) Genomic profiling of fungal cell wall-interfering compounds: identification of a common gene signature. BMC Genom 16:683
Goto N, Hara T, Tsurumi H, Ogawa K, Kitagawa J, Kanemura N et al (2010) Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies. Am J Hematol 85(11):872–876
Gumbo T (2015) Single or 2-dose micafungin regimen for treatment of invasive candidiasis: therapia sterilisans magna! Clin Infect Dis 61(Suppl 6):S635–S642
Hanson KE, Pfeiffer CD, Lease ED, Balch AH, Zaas AK, Perfect JR et al (2012) Beta-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS ONE 7(8):e42282
Hector RF (1993) Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 6(1):1–21
Hector RF, Bierer DE (2011) New beta-glucan inhibitors as antifungal drugs. Expert Opin Ther Pat 21(10):1597–1610
Hindahl CB, Wilson JW (2012) Flash pulmonary oedema during anidulafungin administration. J Clin Pharm Ther 37(4):491–493
Hiramatsu Y, Maeda Y, Fujii N, Saito T, Nawa Y, Hara M et al (2008) Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. Int J Hematol 88(5):588–595
Jimenez-Ortigosa C, Paderu P, Motyl MR, Perlin DS (2014) Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates. Antimicrob Agents Chemother 58(2):1248–1251
Katragkou A, Roilides E, Walsh TJ (2015) Role of echinocandins in fungal biofilm-related disease: vascular catheter-related infections, immunomodulation, and mucosal surfaces. Clin Infect Dis 61(Suppl 6):S622–S629
Knitsch W, Vincent JL, Utzolino S, Francois B, Dinya T, Dimopoulos G et al (2015) A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections. Clin Infect Dis 61(11):1671–1678
Kohno S, Izumikawa K, Ogawa K, Kurashima A, Okimoto N, Amitani R et al (2010) Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect 61(5):410–418
Kojic EM, Darouiche RO (2004) Candida infections of medical devices. Clin Microbiol Rev 17(2):255–267
Koselny KGJ, DiDone L, Glazier V, Krysan K (2016) AR-12, an Antifungal Derivative of Celecoxib, is a Fungal acetyl CoA synthetase inhibitor and modulates the azole and echinocandin susceptibility of resistant candida species. In: 13th ASM Conference on Candida and Candidiasis; April 13–17, 2016; Seattle, WA2016
Koselny K, Green J, Favazzo L, Glazier VE, DiDone L, Ransford S et al (2016b) Antitumor/antifungal celecoxib derivative AR-12 is a non-nucleoside inhibitor of the ANL-family adenylating enzyme Acetyl CoA synthetase. ACS Infect Dis. 2(4):268–280
Kucharikova S, Gerits E, De Brucker K, Braem A, Ceh K, Majdic G et al (2016) Covalent immobilization of antimicrobial agents on titanium prevents Staphylococcus aureus and Candida albicans colonization and biofilm formation. J Antimicrob Chemother 71(4):936–945
Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D et al (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369(9572):1519–1527
Lamoth F, Alexander BD (2015) Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. Antimicrob Agents Chemother 59(7):4308–4311
Lee KK, Maccallum DM, Jacobsen MD, Walker LA, Odds FC, Gow NA et al (2012) Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo. Antimicrob Agents Chemother 56(1):208–217
Lempers VJ, Schouten JA, Hunfeld NG, Colbers A, van Leeuwen HJ, Burger DM et al (2015) Altered micafungin pharmacokinetics in intensive care unit patients. Antimicrob Agents Chemother 59(8):4403–4409
Lepak AJ, Marchillo K, Andes DR (2015) Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother 59(2):1265–1272
Lichtenstern C, Wolff M, Arens C, Klie F, Majeed RW, Henrich M et al (2013) Cardiac effects of echinocandin preparations—three case reports. J Clin Pharm Ther 38(5):429–431
Locke JB, Almaguer AL, Zuill DE, Bartizal K (2016) Characterization of in vitro resistance development to the novel echinocandin CD101 in Candida species. Antimicrob Agents Chemother 60(10):6100–6107. doi:10.1128/AAC.00620-16
Lortholary O, Petrikkos G, Akova M, Arendrup MC, Arikan-Akdagli S, Bassetti M et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clin Microbiol Infect 18(Suppl 7):68–77
Maertens J, Glasmacher A, Herbrecht R, Thiebaut A, Cordonnier C, Segal BH et al (2006) Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107(12):2888–2897
Maertens JA, Madero L, Reilly AF, Lehrnbecher T, Groll AH, Jafri HS et al (2010) A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 29(5):415–420
Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA et al (2015) Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 162(2):81–89
Miesel LL, Lin KY, Chien JC, Hsieh ML, Ong V, Bartizal, K (2016) Efficacy of a novel echinocandin, CD101, in a mouse model of azole-resistant disseminated candidiasis. ASM Microbes 2016; June 16–20, Boston, MA2016
Mizuno H, Sawa M, Yanada M, Shirahata M, Watanabe M, Kato T et al (2013) Micafungin for empirical antifungal therapy in patients with febrile neutropenia: multicenter phase 2 study. Int J Hematol 98(2):231–236
Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J et al (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347(25):2020–2029
Muilwijk EW, Schouten JA, van Leeuwen HJ, van Zanten AR, de Lange DW, Colbers A et al (2014) Pharmacokinetics of caspofungin in ICU patients. J Antimicrob Chemother 69(12):3294–3299
Muilwijk EW, Lempers VJ, Burger DM, Warris A, Pickkers P, Aarnoutse RE et al (2015) Impact of special patient populations on the pharmacokinetics of echinocandins. Expert Rev Anti Infect Ther. 13(6):799–815
Neofytos D, Huang YT, Cheng K, Cohen N, Perales MA, Barker J et al (2015) Safety and efficacy of intermittent intravenous administration of high-dose micafungin. Clin Infect Dis 61(Suppl 6):S652–S661
Neoh CF, Liew D, Slavin M, Marriott D, Chen SC, Morrissey O et al (2011) Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis. J Antimicrob Chemother 66(8):1906–1915
Ong VB, Bartizal K, Hughes D, Miesel L, Lin W, Webb J, Chen A (2016) Optimization of CD101 formulation against Candida albicans in a rat model of vulvovaginal candidiasis (VVC). In: ASM Microbes 2016; June 1–20, Boston, MA2016
Oral SCY-078 vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis [Aug 8, 2016]. ClinicalTrials.gov]. https://clinicaltrials.gov/ct2/show/NCT02244606
Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Betts R, Barron MA et al (2014) MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis 58(9):1219–1226
Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L et al (2016) Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis 62(4):e1–e50
Peleg AY, Hogan DA, Mylonakis E (2010) Medically important bacterial-fungal interactions. Nat Rev Microbiol 8(5):340–349
Perlin DS (2015) Echinocandin resistance in Candida. Clin Infect Dis 61(Suppl 6):S612–S617
Perlin DS (2016) CD101, A novel, long-acting echinocandin provides high plasma exposure that expands in vivo efficacy. In: 13th ASM Conference on Candida and Candidiasis; April 13–17, Seattle, WA2016
Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M (2016) Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates. J Antimicrob Chemother 71(10):2868–2873. doi:10.1093/jac/dkw214
Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M (2013a) Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST). J Antimicrob Chemother 68(4):858–863
Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M (2013b) In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. Antimicrob Agents Chemother 57(2):1065–1068
Pfaller MA, Rhomberg PR, Messer SA, Castanheira M (2015) In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species. Diagn Microbiol Infect Dis 81(4):259–263
Pilmis B, Jullien V, Sobel J, Lecuit M, Lortholary O, Charlier C (2015) Antifungal drugs during pregnancy: an updated review. J Antimicrob Chemother 70(1):14–22
Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, Chotpitayasunondh T et al (2008) Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 27(9):820–826
Ramage G, VandeWalle K, Bachmann SP, Wickes BL, Lopez-Ribot JL (2002) In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 46(11):3634–3636
Ramos-Martin V, O’Connor O, Hope W (2015) Clinical pharmacology of antifungal agents in pediatrics: children are not small adults. Curr Opin Pharmacol 24:128–134
Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D et al (2007) Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356(24):2472–2482
Saliba F, Pascher A, Cointault O, Laterre PF, Cervera C, De Waele JJ et al (2015) Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients. Clin Infect Dis 60(7):997–1006
Sandison T, Ong V, Lee J, Thye D (2017) Safety and Pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults. Antimicrob Agents Chemother 61(2). doi:10.1128/AAC.01627-16
Schneeweiss S, Carver PL, Datta K, Galar A, Johnson MD, Johnson MG et al (2016) Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. J Antimicrob Chemother 71(10):2938–2944. doi:10.1093/jac/dkw225
Shah PJ, Sundareshan V, Miller B, Bergman SJ (2016) Micafungin and a case of polymorphic ventricular tachycardia. J Clin Pharm Ther 41(3):362–364
Shuford JA, Rouse MS, Piper KE, Steckelberg JM, Patel R (2006) Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model. J Infect Dis 194(5):710–713
Singh N, Limaye AP, Forrest G, Safdar N, Munoz P, Pursell K et al (2006) Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 81(3):320–326
Sinnollareddy MG, Roberts JA, Lipman J, Akova M, Bassetti M, De Waele JJ et al (2015) Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. Crit Care 19:33
Steinbach WJ, Lamoth F, Juvvadi PR (2015) Potential microbiological effects of higher dosing of echinocandins. Clin Infect Dis 61(Suppl 6):S669–S677
Stover KR, Farley JM, Kyle PB, Cleary JD (2014) Cardiac toxicity of some echinocandin antifungals. Expert Opin Drug Saf 13(1):5–14
Timsit JF, Azoulay E, Cornet M, Gangneux JP, Jullien V, Vesin A et al (2013) EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial. Trials 14:399
Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 18(Suppl 7):53–67
Valiante V, Monteiro MC, Martin J, Altwasser R, El Aouad N, Gonzalez I et al (2015) Hitting the caspofungin salvage pathway of human-pathogenic fungi with the novel lasso peptide humidimycin (MDN-0010). Antimicrob Agents Chemother 59(9):5145–5153
Vallabhaneni S, Cleveland AA, Farley MM, Harrison LH, Schaffner W, Beldavs ZG et al (2015) Epidemiology and risk factors for echinocandin nonsusceptible candida glabrata bloodstream infections: data from a large multisite population-based Candidemia Surveillance Program, 2008–2014. Open Forum Infect Dis 2(4):ofv163
van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH et al (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39(10):1407–1416
Walker LA, Munro CA, de Bruijn I, Lenardon MD, McKinnon A, Gow NA (2008) Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog 4(4):e1000040
Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A et al (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351(14):1391–1402
Wheeler RT, Fink GR (2006) A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog 2(4):e35
Winston DJ, Limaye AP, Pelletier S, Safdar N, Morris MI, Meneses K et al (2014) Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am J Transplant 14(12):2758–2764
Zhao Y, Nagasaki Y, Kordalewska M, Press EG, Shields RK, Nguyen MH et al (2016) Rapid detection of FKS-associated echinocandin resistance in Candida glabrata. Antimicrob Agents Chemother 60(11):6573–6577. doi:10.1128/AAC.01574-16
Acknowledgements
CCC is an Australian National Health and Medical Research Council (NHMRC) Early Career Fellow (1092160).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declared that there is no conflict of interest. SC-AC and MAS are members of the Antifungal Advisory Boards of Gilead Sciences Inc., Merck, and Pfizer, Australia, and have received untied investigator-initiated grants from Pfizer Australia, Gilead Sciences and Merck.
Rights and permissions
About this article
Cite this article
Chang, C.C., Slavin, M.A. & Chen, S.CA. New developments and directions in the clinical application of the echinocandins. Arch Toxicol 91, 1613–1621 (2017). https://doi.org/10.1007/s00204-016-1916-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-016-1916-3